Excellence in Pediatrics Institute
Think Rare Program
Think Rare Program  ·  Alpha-Mannosidosis (AM) October 2026

This Issue

Join the New Free Think Rare Webinar:
Not All Alpha-Mannosidosis Looks Severe

Register to attend live or watch the video on demand after the session concludes.

Context

Alpha-mannosidosis (AM) is a rare, progressive lysosomal storage disorder with a broad and variable clinical presentation. In its milder forms, it may present with subtle cognitive, motor, or developmental features that seem too modest to raise suspicion of a rare disease – leading to false reassurance, fragmented care, and a “watch and wait” approach that can delay diagnosis for years.

The Think Rare AM webinar series continues on Wednesday, 7 October with a session dedicated to these mild and attenuated presentations. Built around a real-world case, it focuses on the decision points where earlier action could have shortened the diagnostic pathway.

Missed the first webinar on recognizing AM behind recurrent ENT infections, hearing loss, and developmental concerns? It is now available on demand – see below.

Explore the Think Rare Program →

Upcoming Webinar 2 • Wednesday, 7 October

Wednesday, 7th October 2026
13:00 Central European Summer Time (CEST) · Virtual · 60 minutes

Speakers: Dr. Karolina Stepien · Dr. João Durães

Not All Alpha-Mannosidosis Looks Severe: Recognizing Mild and Attenuated Forms in Everyday Pediatric Practice

Mild and attenuated presentations of Alpha-Mannosidosis are commonly overlooked because they don’t appear severe enough to trigger suspicion of a rare disease. Dr. Karolina Stepien frames why milder forms are the most commonly missed and places them in the context of emerging evidence on diagnostic delay, while Dr. João Durães walks through real-world AM cases – from presenting features and consultation timeline to the decision points that could have shortened the pathway.

Who should attend: general pediatricians, general practitioners, pediatric neurologists, and community pediatric specialists.

Bring your questions: the faculty discussion at the end of the webinar will explore what earlier recognition would have required, which triggers are most useful in everyday settings, and how frontline clinicians can be supported to act sooner.

Register for Webinar 2 →

Key Learning Points from the Webinar

At the end of the webinar, participants will be able to:

1

Recognize Mild and Attenuated AM

Recognize mild and attenuated presentations of AM, including subtle cognitive, motor, or developmental features.

2

Overcome False Reassurance

Understand how false reassurance and symptom fragmentation contribute to diagnostic delay in milder phenotypes.

3

Shorten the Diagnostic Pathway

Apply real-world case lessons to shorten the diagnostic pathway in everyday practice.

Also Coming Up • Webinar 3 • Wednesday, 28 October

Wednesday, 28th October 2026
13:00 Central European Time (CET)

What Matters Most? Monitoring Progression and Evaluating Treatment Impact in Alpha-Mannosidosis

Now that disease-modifying treatment is available, what should be assessed at diagnosis, and how should patients be monitored over time? Led by Dr. Agne Kerpauskiene and Dr. Mónica López Rodríguez, the session outlines a practical framework for baseline assessment and longitudinal monitoring using validated clinical scales, applied to a real treated AM case.

Register for Webinar 3 →

Key Learning Points from Webinar 3

At the end of the webinar, participants will be able to:

Building a Baseline Assessment

Establish a structured baseline assessment framework at diagnosis, covering cognitive, motor, functional, and quality-of-life domains.

Applying Validated Clinical Scales

Identify and apply validated clinical scales relevant to AM monitoring, including how to interpret stability, improvement, and progression.

Monitoring Over Time

Define expected clinical trajectories over the first 12 months and recognize deviations that signal progression or treatment response.

Overcoming Implementation Barriers

Understand the barriers to structured monitoring in routine practice, and how to integrate a practical framework into real-world follow-up.

Missed It? • Webinar 1 • Now On Demand

Webinar 1: The Child Who Keeps Coming Back — watch on demand

The Child Who Keeps Coming Back: Recognizing AM Behind Recurrent ENT Infections, Hearing Loss, and Developmental Concerns

Dr. Cláudia Falcão Reis · Prof. Mehmet Umut Akyol · Recorded 16 September 2026

Learn to connect symptoms that are often managed in isolation across specialties, recognize the pattern that should raise suspicion of AM, and know when to escalate to metabolic referral.

Watch On Demand →

Disclaimer

This webinar is intended for healthcare professionals only. It is part of the THINK RARE program, which EIP develops and manages independently with respect to content, topics, and speaker selection. EIP seeks unrestricted grants to support its activities; Chiesi Farmaceutici S.p.A. has provided one to partially support EIP’s work on early diagnosis of metabolic disorders.

About the Program

The EiP Think Rare Program empowers pediatricians and general practitioners to identify rare and underdiagnosed conditions early. The program currently covers MPS, MLD, AM, and CLN2 (Batten disease), forming a practical, centralized resource for recognizing rare diseases in clinical practice.

Explore the Learning Zones

Each Learning Zone focuses on a specific rare disease, equipping you with condition-specific knowledge, early signs to watch for, and up-to-date clinical resources. Explore all zones to build both depth in individual conditions and a broader understanding of how rare diseases present in practice.

Mucopolysaccharidosis (MPS)

Explore practical resources to help detect early signs, reduce misdiagnosis, and ensure timely referrals and intervention.

Visit Zone →

Metachromatic Leukodystrophy (MLD)

Recognize early signs often mistaken for common conditions and take action sooner to change the course of a child’s life.

Visit Zone →

Alpha-Mannosidosis (AM)

Recognize the early signs and transform outcomes with earlier, more accurate referral and patient care.

Visit Zone →

Neuronal Ceroid Lipofuscinosis (CLN2)

Explore practical resources on CLN2 (Batten disease), from early recognition to multidisciplinary management and treatment.

Visit Zone →